Becton Dickinson and Company (BDX)vsStereotaxis Inc (STXS)
BDX
Becton Dickinson and Company
$158.27
+1.51%
HEALTHCARE · Cap: $56.49B
STXS
Stereotaxis Inc
$1.88
+4.17%
HEALTHCARE · Cap: $174.08M
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 67615% more annual revenue ($21.92B vs $32.38M). BDX leads profitability with a 8.0% profit margin vs -66.8%. BDX appears more attractively valued with a PEG of 1.16. BDX earns a higher WallStSmart Score of 61/100 (C+).
BDX
Buy61
out of 100
Grade: C+
STXS
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.9%
Fair Value
$286.42
Current Price
$158.27
$128.15 discount
Intrinsic value data unavailable for STXS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Revenue surging 36.3% year-over-year
Areas to Watch
Moderate valuation
1.6% revenue growth
ROE of 7.0% — below average capital efficiency
Distress zone — elevated risk
Trading at 13.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -143.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bull Case : STXS
The strongest argument for STXS centers on Revenue Growth. Revenue growth of 36.3% demonstrates continued momentum. PEG of 1.31 suggests the stock is reasonably priced for its growth.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : STXS
The primary concerns for STXS are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
BDX profiles as a value stock while STXS is a hypergrowth play — different risk/reward profiles.
STXS carries more volatility with a beta of 1.40 — expect wider price swings.
STXS is growing revenue faster at 36.3% — sustainability is the question.
BDX generates stronger free cash flow (549M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (61/100 vs 34/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Stereotaxis Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (MRI) systems for use in the hospital's interventional operating room to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. The company is headquartered in St. Louis, Missouri.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?